Top

Published in:

01-05-2019 | Cancer Immunotherapy | Original Article

Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model

Authors: Jamile R. Silva, Natiely S. Sales, Mariângela O. Silva, Luana R. M. M. Aps, Ana C. R. Moreno, Elaine G. Rodrigues, Luís C. S. Ferreira, Mariana O. Diniz

Published in: Cancer Immunology, Immunotherapy | Issue 5/2019

Abstract

The presence of IL-10, produced either by tumor cells or immunosuppressive cells, is frequently associated with a poor prognosis for cancer progression. It may also negatively impact anticancer treatments, such as immunotherapies, that otherwise would promote the activation of cytotoxic T cells capable of detecting and destroying malignant cells. In the present study, we evaluated a new adjuvant approach for anticancer immunotherapy using a plasmid vector encoding a soluble form of the IL-10 receptor (pIL-10R). pIL-10R was coadministered to mice with a DNA vaccine encoding the type 16 human papillomavirus (HPV-16) E7 oncoprotein genetically fused with glycoprotein D of herpes simplex virus (HSV) (pgDE7h). Immunization regimens based on the coadministration of pIL-10R and pgDE7h enhanced the antitumor immunity elicited in mice injected with TC-1 cells, which express HPV-16 oncoproteins. The administration of the DNA vaccines by in vivo electroporation further enhanced the anticancer effects of the vaccines, leading to the activation of tumor-infiltrating polyfunctional E7-specific cytotoxic CD8⁺ T cells and control of the expansion of immunosuppressive cells. In addition, the combination of immunotherapy and pIL-10R allowed the control of tumors in more advanced growth stages that otherwise would not be treatable by the pgDE7h vaccine. In conclusion, the proposed treatment involving the expression of IL-10R enhanced the antitumor protective immunity induced by pgDE7h administration and may contribute to the development of more efficient clinical interventions against HPV-induced tumors.

Available only for authorised users

Yaddanapudi K, Mitchell RA, Eaton JW (2013) Cancer vaccines: looking to the future. Oncoimmunology 2:1–7. https://doi.org/10.4161/onci.23403 CrossRef

Azar KK, Tani M, Yasuda H et al (2004) Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol 35:1376–1384. https://doi.org/10.1016/j.humpath.2004.08.012 CrossRefPubMed

Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM et al (2008) Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest 26:1037–1043. https://doi.org/10.1080/07357900802112693 CrossRefPubMed

Syrjänen S, Naud P, Sarian L et al (2009) Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort. Virchows Arch 455:505–515. https://doi.org/10.1007/s00428-009-0850-7 CrossRefPubMed

Berti FCB, Pereira APL, Cebinelli GCM et al (2017) The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma. Cytokine Growth Factor Rev 34:1–13. https://doi.org/10.1016/j.cytogfr.2017.03.002 CrossRefPubMed

Alcocer-González JM, Berumen J, Taméz-Guerra R et al (2006) In Vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 19:481–491. https://doi.org/10.1089/vim.2006.19.481 CrossRefPubMed

Chuang C-Y, Sung W-W, Wang L et al (2012) Differential Impact of IL-10 expression on survival and relapse between HPV16-positive and -negative oral squamous cell carcinomas. PLoS One 7:e47541. https://doi.org/10.1371/journal.pone.0047541 CrossRefPubMedPubMedCentral

Bornstein S, Schmidt M, Choonoo G et al (2016) IL-10 and integrin signaling pathways are associated with head and neck cancer progression. BMC Genom 17:38. https://doi.org/10.1186/s12864-015-2359-6 CrossRef

Chen L, Qiu M, He W et al (2012) Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro. Mol Biol Rep 39:6633–6639. https://doi.org/10.1007/s11033-012-1468-4 CrossRefPubMed

10.

ten Broeke T, Wubbolts R, Stoorvogel W (2013) MHC class II antigen presentation by dendritic cells regulated through endosomal sorting. Cold Spring Harb Perspect Biol 5:a016873. https://doi.org/10.1101/cshperspect.a016873 CrossRefPubMedPubMedCentral

11.

Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111–165. https://doi.org/10.1016/B978-0-12-380995-7.00004-5 CrossRefPubMedPubMedCentral

12.

García-Rocha R, Moreno-Lafont M, Mora-García ML et al (2015) Mesenchymal stromal cells derived from cervical cancer tumors induce TGF-β1 expression and IL-10 expression and secretion in the cervical cancer cells, resulting in protection from cytotoxic T cell activity. Cytokine 76:382–390. https://doi.org/10.1016/j.cyto.2015.09.001 CrossRefPubMed

13.

Sevko A, Umansky V (2013) Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: Thick as thieves. J Cancer 4:3–11. https://doi.org/10.7150/jca.5047 CrossRefPubMed

14.

Song X, Guo W, Cui J et al (2011) A tritherapy combination of a fusion protein vaccine with immune-modulating doses of sequential chemotherapies in an optimized regimen completely eradicates large tumors in mice. Int J Cancer 128:1129–1138. https://doi.org/10.1002/ijc.25451 CrossRefPubMed

15.

Kim JH, Kang TH, Noh KH et al (2011) Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency. Clin Exp Immunol 165:180–189. https://doi.org/10.1111/j.1365-2249.2011.04410.x CrossRefPubMedPubMedCentral

16.

Ahn YH, Hong SO, Kim JH et al (2015) The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8 + T cell immunity. Clin Exp Immunol 181:164–178. https://doi.org/10.1111/cei.12620 CrossRefPubMedPubMedCentral

17.

Marchi LHL, Paschoalin T, Travassos LR, Rodrigues EG (2011) Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther 18:110–122. https://doi.org/10.1038/cgt.2010.58 CrossRefPubMed

18.

Diniz MO, Cariri FAMO, Aps LRMM, Ferreira LCS (2013) Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors. Hum Gene Ther 24:861–870. https://doi.org/10.1089/hum.2013.102 CrossRefPubMed

19.

Porchia BFMM, Diniz MO, Cariri FAMO et al (2011) Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8 + T cell responses and confers protective antitumor immunity. Mol Pharm 8:2320–2330. https://doi.org/10.1021/mp200194s CrossRefPubMed

20.

Diniz MO, Lasaro MO, Ertl HC, Ferreira LCS (2010) Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D. Clin Vaccine Immunol 17:1576–1583. https://doi.org/10.1128/CVI.00264-10 CrossRefPubMedPubMedCentral

21.

Lin KY, Guarnieri FG, Staveley-O’Carroll KF et al (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21–26PubMed

22.

Diniz MO, Sales NS, Silva JR, Ferreira LCS (2016) Protection against HPV-16-associated tumors requires the activation of CD8 + effector memory T cells and the control of myeloid-derived suppressor cells. Mol Cancer Ther 15:1920–1930. https://doi.org/10.1158/1535-7163.MCT-15-0742 CrossRefPubMed

23.

Lee S-H, Danishmalik SN, Sin J-I (2015) DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother 11:1889–1900. https://doi.org/10.1080/21645515.2015.1035502 CrossRefPubMedPubMedCentral

24.

Ni G, Wang T, Walton S et al (2015) Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol 293:126–129. https://doi.org/10.1016/j.cellimm.2014.12.012 CrossRefPubMed

25.

Gothelf A, Gehl J (2012) What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother 8:1694–1702. https://doi.org/10.4161/hv.22062 CrossRefPubMedPubMedCentral

26.

Sales NS, Silva JR, Aps LRMM et al (2017) In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8 + T cells. Vaccine. https://doi.org/10.1016/j.vaccine.2017.11.011 CrossRefPubMed

27.

Trimble CL, Morrow MP, Kraynyak KA et al (2015) Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet 386:2078–2088. https://doi.org/10.1016/S0140-6736(15)00239-1 CrossRefPubMedPubMedCentral

28.

De Rosa SC, Lu FX, Yu J et al (2004) Vaccination in humans generates broad T cell cytokine responses. J Immunol 173:5372–5380CrossRefPubMed

29.

Precopio ML, Betts MR, Parrino J et al (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204:1405–1416. https://doi.org/10.1084/jem.20062363 CrossRefPubMedPubMedCentral

30.

Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D et al (2009) Self-antigen-specific CD8 + T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206:849–866. https://doi.org/10.1084/jem.20081382 CrossRefPubMedPubMedCentral

31.

Kim TJ, Jin H-T, Hur S-Y et al (2014) Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 5:5317. https://doi.org/10.1038/ncomms6317 CrossRefPubMedPubMedCentral

32.

Li O (2013) The paradox of IL–10–mediated modulation in cervical cancer (Review). Biomed Reports. https://doi.org/10.3892/br.2013.69 CrossRef

33.

Wilke CM, Wei S, Wang L et al (2011) Dual biological effects of the cytokines interleukin-10 and interferon-γ. Cancer Immunol Immunother 60:1529–1541. https://doi.org/10.1007/s00262-011-1104-5 CrossRefPubMed

34.

Santin AD, Hermonat PL, Ravaggi A et al (2000) Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74:4729–4737CrossRefPubMedPubMedCentral

35.

Wang Y, Liu X-H, Li Y-H, Li O (2013) The paradox of IL-10-mediated modulation in cervical cancer. Biomed Rep 1:347–351. https://doi.org/10.3892/br.2013.69 CrossRefPubMedPubMedCentral

36.

Li L, Ma Y, Liu S et al (2016) Interleukin 10 promotes immune response by increasing the survival of activated CD8 + T cells in human papillomavirus 16-infected cervical cancer. Tumor Biol 37:16093–16101. https://doi.org/10.1007/s13277-016-5466-3 CrossRef

37.

Chen S, Ni G, Wu X et al (2016) Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice. Cell Immunol 300:9–17. https://doi.org/10.1016/j.cellimm.2015.11.002 CrossRefPubMed

38.

Ahrends T, Baba a N, Xiao Y et al (2016) CD27 agonism plus PD-1 blockade recapitulates CD4 + T-cell help in therapeutic anticancer vaccination. Cancer Res 76:2921–2931. https://doi.org/10.1158/0008-5472.CAN-15-3130 CrossRefPubMed

39.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G (2013) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73:3591–3603. https://doi.org/10.1158/0008-5472.CAN-12-4100 CrossRefPubMedPubMedCentral

Title: Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model
Authors: Jamile R. Silva
Natiely S. Sales
Mariângela O. Silva
Luana R. M. M. Aps
Ana C. R. Moreno
Elaine G. Rodrigues
Luís C. S. Ferreira
Mariana O. Diniz
Publication date: 01-05-2019
Publisher: Springer Berlin Heidelberg
Keyword: Cancer Immunotherapy
Published in: Cancer Immunology, Immunotherapy / Issue 5/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-02297-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT

An alphavirus-based therapeutic cancer vaccine: from design to clinical trial

Imbalances in cellular immunological parameters in blood predetermine tumor onset in a natural mouse model of breast cancer

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Opposing roles of eosinophils in cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer